A study of Prasrini taila administration through nasal and through anus in treatment of Cervical spondylosis.

An Open Randomised Clinical Study to Evaluate the Comparative Efficacy of Nasya and Matra Basti with Prasarini Taila in the Management of Greevastambh w.s.r. to Cervical Spondylosis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/10/015990

Enrollment

Registered

2018-10-10

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M478- Other spondylosis

Interventions

Intervention1: Nasal administration of Parsarini Taila in the dose of 8 drops (6ml)in each nostril once a day for 14 days.: Nasal administration of Parsarini Taila in the dose of 8 drops (6ml)in each

Eligibility

Inclusion criteria

Inclusion criteria: (1)Patients with features of Greevastambh (Cervical spondylosis) (2)Patients fit for Nasya and Matra Basti. (3)Patients having sign and symptoms supported by X-ray findings as per Visual Analog Scale, Modified Japanese Orthopedic Score)

Exclusion criteria

Exclusion criteria: (1)Patients suffering from rheumatoid arthritis, gout, ankylosing spondylitis. (2)Patients with major systemic disorders. (3)Patients with stenosis of spinal canal, myelopathy. (4)Pregnant women and lactating mother. (5)Patients with any surgical history at cervical region.

Design outcomes

Primary

Measure	Time frame
changes in modified Japanes orthopaedic association score (mJOA score) and range of movementTimepoint: 45 days	—

Secondary

Measure	Time frame
changes in VAS score and global assessement of disease activity.Timepoint: 45 days	—

Countries

India

Contacts

Public ContactDr Saroj Kumari

National Institute of Ayurveda JaipurÂ

sarveshksingh21@gmail.com8739860237

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026